• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Lineage Cell Therapeutics

Monday, June 03, 2024
CP
Regenerative Medicine
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, differentiated, and allogeneic human cell therapies. Lineage’s clinical and preclinical programs include five product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy being developed for the treatment of geographic atrophy under a worldwide collaboration with Roche and Genentech; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a for the treatment of spinal cord injury; (iii) VAC2, a dendritic cell therapy in Phase 1 for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for hearing loss treatment; and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss.
Lineage Cell Therapeutics
Company Website: https://lineagecell.com/
Lead Product in Development: OpRegen
Number Of Unlicensed Products (For Which You Are Seeking Partners): 4

Exchange

NYSE

Ticker

LCTX

Website

https://lineagecell.com/

Company HQ City

Carlsbad

Company HQ State

CA

Company HQ Country

United States

CEO/Top Company Official

Brian Culley

Lead Product in Development

OpRegen

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS